חוב כולל להון Kairos Pharma Ltd (KAPA)

Kairos Pharma Ltd (KAPA) faces uncertainty regarding new drug test results and the search for partners, yet relies on a dedicated staff of scientists motivated by stock options. This chart of the total debt-to-equity ratio captures a value of 0.00. The business focuses on developing a targeted immune response system, which could radically shift therapy standards for lung and prostate tumors.

The implementation of AI in molecular design and the automation of drug synthesis at Kairos Pharma Ltd (KAPA) optimize drug development costs. The ratio of total liabilities to equity determines the degree of financial leverage, allowing an investor to assess the company's dependence on borrowed capital through changes in the proportion of total debt to equity.